CSIR developed affordable Corona Virus Tablets, critical patients survive

0
136
CSIR developed affordable Corona Virus Tablets, critical patients survive
CSIR developed affordable Corona Virus Tablets, critical patients survive

CSIR developed affordable Corona Virus Tablets, critical patients survive

Cipla has started manufacturing this COVID19 drug and has sought permission from the Drug Controller General of India (DCGI) to land the drug in the Indian market. The Controller General has allowed the use of Favipiravir in the country in emergencies. Cipla is now bringing this medicine to help patients suffering from Covid-19.

Consider it as good news on Friday. The drug of Coronavirus, prepared in India, is ready for launch. The main thing about this Indian drug is that it is very cheap and is also very effective in fighting the corona epidemic. The pharmaceutical company Cipla is fully prepared to launch favipiravir, a drug developed by the Council of Scientific and Industrial Research (CSIR) to treat Covid-19.

According to an official statement, the results during the clinical trial of Fevipir, originally developed by Fuji Pharma of Japan(Fuji Pharma), have been good, especially in patients with mild and mid-symptoms of Vikid-19. CSIR discovered and delivered the cheap process of making this drug using locally available chemicals.

According to the statement, Cipla has started its construction and sought permission from the Drug Controller General of India (DCGI) to land the drug in the Indian market. The Controller General has allowed the use of favipir in the country in case of emergency. Cipla is now bringing this medicine to help patients suffering from Covid-19.

In this regard, Director, CSIR-IICR, S. Chandrasekhar says the technology is very affordable and effective. This will help Cipla produce more drugs in a short time.

LEAVE A REPLY

Please enter your comment!
Please enter your name here